Next Generation DYRK1A Inhibitors

NEXT GENERATION DYRK1A INHIBITORS

Brickell Bio’s next generation compound library comes with the ability to efficiently penetrate the blood-brain-barrier, presenting the potential to address high unmet need neuroinflammatory conditions, including tauopathies such as Alzheimer’s disease and Down’s Syndrome.

Brickell plans to select a lead next generation DYRK1A inhibitor candidate for IND-enabling studies to potentially treat neuroinflammatory conditions in 2022, followed by additional preclinical studies to further inform the future indication and development strategy for this program.

LEARN MORE ABOUT DYRK1A IN NEUROINFLAMMATORY DISEASES